- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07948252
Phrenic Nerve-Guided Interscalene Block: Diaphragm Paralysis and Analgesia
The Effect of Using the Phrenic Nerve as a Landmark During Ultrasound-Guided Interscalene Block on the Incidence of Diaphragmatic Paralysis and Analgesic Efficacy in Patients Scheduled for Shoulder Surgery: A Prospective, Randomized Study
The primary objective of this prospective clinical study is to evaluate the incidence of hemidiaphragmatic paralysis when the phrenic nerve is utilized as a primary sonographic landmark during interscalene brachial plexus blocks. While interscalene blocks provide excellent analgesia for shoulder surgeries, they are frequently associated with unintended phrenic nerve blockade, leading to diaphragmatic paresis or paralysis. This study hypothesizes that utilizing the phrenic nerve as a specific landmark to guide local anesthetic injection will [reduce] the frequency of diaphragmatic paralysis while maintaining adequate surgical anesthesia.
Study Overview
Status
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: BARAN NAS
- Phone Number: 00905547501481
- Email: hessam_nas@hotmail.com
Study Contact Backup
- Name: Müge ÇAKIRCA
- Phone Number: 00905054433177
- Email: mugecakirca@gmail.com
Study Locations
-
-
Altindağ
-
Ankara, Altindağ, Turkey (Türkiye), 06000
- Ankara Etlik City Hospital
-
Contact:
- BARAN NAS
- Phone Number: 00905547501481
- Email: hessam_nas@hotmail.com
-
Contact:
- MUGE ÇAKIRCA
- Phone Number: 00905054433177
- Email: mugecakirca@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged between 18 and 75 years.
- American Society of Anesthesiologists (ASA) physical status I, II, or III.
- Scheduled for elective arthroscopic shoulder surgery.
- Patients who are informed about the study and provide written informed consent.
Exclusion Criteria:
- Known allergy to local anesthetics.
- Presence of infection at the application/injection site.
- Severe coagulopathy disorder or the use of anticoagulants.
- Diagnosis of contralateral phrenic nerve palsy or severe Chronic Obstructive
- Pulmonary Disease (COPD).
- History of chronic opioid use or neuropathic pain.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Active Comparator: Intrafascial Injection Group
In this group, interscalene anatomical structures and the phrenic nerve will be visualized under ultrasound guidance. A volume of 10 ml of local anesthetic solution will be injected directly into the brachial plexus sheath (intrafascial plane) |
Under ultrasound guidance, the interscalene brachial plexus and the phrenic nerve will be directly visualized on the anterior scalene muscle to be used as a landmark. A total of 10 ml of [Local anesthetic medication name, e.g., 0.5% Bupivacaine] solution will be injected strictly into the intrafascial plane, inside the nerve sheath |
|
Experimental: Experimental: Extrafascial Injection Group
In this group, interscalene anatomical structures and the phrenic nerve will be visualized under ultrasound guidance. A volume of 10 ml of local anesthetic solution will be injected outside the brachial plexus nerve sheath (extrafascial plane) |
Under ultrasound guidance, the interscalene brachial plexus and the phrenic nerve will be directly visualized on the anterior scalene muscle to be used as a landmark. A total of 10 ml of [Local anesthetic medication name, e.g., 0.5% Bupivacaine] solution will be injected strictly into the extrafascial plane, outside the nerve sheath |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Transient Hemidiaphragmatic Paralysis
Time Frame: At postoperative minute 0 and minute 30
|
The incidence of transient diaphragmatic paralysis (phrenic nerve paresis) will be evaluated by measuring diaphragmatic excursion using diaphragm ultrasonography |
At postoperative minute 0 and minute 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative Pain Scores
Time Frame: Postoperative 1st, 3rd, 6th, 12th, and 24th hours
|
Postoperative pain severity will be assessed using the Numeric Rating Scale (NRS). The scale ranges from 0 to 10, where 0 represents 'no pain' and 10 represents 'worst imaginable pain'. Higher scores indicate a worse outcome (more severe pain) |
Postoperative 1st, 3rd, 6th, 12th, and 24th hours
|
|
Postoperative Total Opioid Consumption
Time Frame: Postoperative 1st, 3rd, 6th, 12th, and 24th hours
|
The amount of total opioid consumption will be recorded during the postoperative follow-up period |
Postoperative 1st, 3rd, 6th, 12th, and 24th hours
|
|
Incidence of Dyspnea
Time Frame: Up to 24 hours postoperatively
|
The presence of shortness of breath (dyspnea) complaints from the patients will be evaluated and recorded |
Up to 24 hours postoperatively
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: BARAN NAS, Ankara Etlik City Hospital (Ankara Etlik Sehir Hastanesi)
- Principal Investigator: MÜGE ÇAKIRCA, Ankara Etlik City Hospital (Ankara Etlik Sehir Hastanesi)
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AEŞH-EK-2026-133
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.